MEDCITY NEWS | We are living through the worst pandemic in a century, and infectious disease experts in the are sounding the alarm that drug-resistant bacteria will lead to another public health crisis. Misaligned market incentives related to development of antibiotics mean that necessary pharmacological innovations are deemed irrational investments. That means the burden is on the government to invest in these initiatives for the sake of public health. The constellation of US actors fighting antimicrobial resistance seek support for two new legislative fixes: the DISARM (Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms) Act and the PASTEUR (Pioneering Antimicrobial Subscriptions to End Upsurging Resistance) Act. Together, the two support higher reimbursement rates and bulk purchasing of novel antibiotics.